Offer - Urjas Oil for just ₹ 1 X
Pamorelin LA 11.25 Injection, a prescription drug, is manufactured in various forms such as Injection. Primarily, it is used for the treatment of Prostate Cancer. Other than this, Pamorelin LA 11.25 Injection has some other therapeutic uses, which have been discussed ahead.
The right dosage of Pamorelin LA 11.25 Injection depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
The side effects typically associated with Pamorelin LA 11.25 Injection include Excessive sweating, Paresthesia. While these are the most often observed Pamorelin LA 11.25 Injection side effects, there are can be others also. These have been listed below. Usually, these side effects of Pamorelin LA 11.25 Injection go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Pamorelin LA 11.25 Injection's effect is Severe during pregnancy and Severe for lactating mothers. Further, the section on Pamorelin LA 11.25 Injection related warnings talks about Pamorelin LA 11.25 Injection's effects on the liver, heart and kidney.
The section on Pamorelin LA 11.25 Injection contraindications lists all such conditions.
Drug reaction of Pamorelin LA 11.25 Injection with other medicines has been reported. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Pamorelin LA 11.25 Injection is considered not safe while driving, and is not addictive.
Pamorelin LA 11.25 Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Male) |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Pamorelin LA 11.25 Injection safe for pregnant women?
Pamorelin LA has many dangerous side effects in pregnant women. If you are pregnant, do not consume Pamorelin LA without medical advice.
Is the use of Pamorelin LA 11.25 Injection safe during breastfeeding?
Women who are breastfeeding, may experience serious side effects after taking Pamorelin LA. So it is adviced to consult the doctor before using it.
What is the effect of Pamorelin LA 11.25 Injection on the Kidneys?
Pamorelin LA rarely harms the kidneys.
What is the effect of Pamorelin LA 11.25 Injection on the Liver?
Side effects of Pamorelin LA rarely affect the liver.
What is the effect of Pamorelin LA 11.25 Injection on the Heart?
Use of Pamorelin LA may be dangerous for the heart. Do not use it without doctor's advice.
If you are suffering from any of the following diseases, you should not take Pamorelin LA 11.25 Injection unless your doctor advises you to do so -
Is this Pamorelin LA 11.25 Injection habit forming or addictive?
Pamorelin LA 11.25 Injection is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Pamorelin LA 11.25 Injection. So it is best to avoid driving.
Is it safe?
Yes, but consume Pamorelin LA 11.25 Injection only on doctor's advice.
Is it able to treat mental disorders?
No, Pamorelin LA 11.25 Injection is not used to treat mental disorders.
Interaction between Food and Pamorelin LA 11.25 Injection
Due to the absence of research, it is difficult to say how Pamorelin LA 11.25 Injection and food will interact.
Interaction between Alcohol and Pamorelin LA 11.25 Injection
Information about the interaction of Pamorelin LA 11.25 Injection and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 53
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 242-243
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Trelstar® (triptorelin pamoate)